标题
Novel Drugs with High Efficacy against Tumor Angiogenesis
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 13, Pages 6934
出版商
MDPI AG
发表日期
2022-06-23
DOI
10.3390/ijms23136934
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- (2022) Charles C Wykoff et al. LANCET
- Extracellular HSPs: The Potential Target for Human Disease Therapy
- (2022) Dong-Yi Li et al. MOLECULES
- The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition
- (2021) Sophia Daum et al. Frontiers in Cell and Developmental Biology
- Angiopoietin inhibitors: A review on targeting tumor angiogenesis
- (2021) Digna Parmar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
- (2021) Martina Spisarová et al. Expert Review of Anticancer Therapy
- Effect of Exogenous Melatonin on the Development of Mice Ovarian Follicles and Follicular Angiogenesis
- (2021) Jingli Tao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 3D tumor angiogenesis models: recent advances and challenges
- (2021) Sharath M. Bhat et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Targeting Tie2 in the Tumor Microenvironment: From Angiogenesis to Dissemination
- (2021) Camille L. Duran et al. Cancers
- Weibel Palade Bodies: Unique Secretory Organelles of Endothelial Cells that Control Blood Vessel Homeostasis
- (2021) Johannes Naß et al. Frontiers in Cell and Developmental Biology
- HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis
- (2020) Yanling Niu et al. CANCER RESEARCH
- Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan
- (2020) Teruo Inamoto et al. Expert Review of Anticancer Therapy
- HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer
- (2020) Ryoji Eguchi et al. ONCOLOGY REPORTS
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
- (2020) Josep Garcia et al. CANCER TREATMENT REVIEWS
- Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma
- (2020) Seon-Hyeong Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
- (2020) Kayoko Hosaka et al. Nature Communications
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
- (2020) Arshad M. Khanani et al. JAMA Ophthalmology
- Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells
- (2020) Bogdana Kovalchuk et al. CLINICAL & EXPERIMENTAL METASTASIS
- The role of microenvironment in tumor angiogenesis
- (2020) Xianjie Jiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
- (2020) Florian Heil et al. Translational Oncology
- Extended (≥q12 Weeks) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular AMD: Post Hoc Analysis of VIEW Trials
- (2019) Rahul N. Khurana et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies
- (2019) Tiziana Annese et al. Cancers
- Simultaneous Inhibition of Angiopoietin-2 and VEGF-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial
- (2019) Jayashree Sahni et al. OPHTHALMOLOGY
- AT-533, a Hsp90 inhibitor, attenuates HSV-1-induced inflammation
- (2019) Feng Li et al. BIOCHEMICAL PHARMACOLOGY
- Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model
- (2019) Thomas Mueller et al. MOLECULES
- 74TiPPhase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
- (2019) K Yamazaki et al. ANNALS OF ONCOLOGY
- AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo
- (2019) Peng-Chao Zhang et al. BIOCHEMICAL PHARMACOLOGY
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
- (2019) Raluca Ioana Teleanu et al. Journal of Clinical Medicine
- Antiangiogenic compounds: well-established drugs versus emerging natural molecules
- (2018) Andreia Ribeiro et al. CANCER LETTERS
- Vascular endothelial growth factor signaling in development and disease
- (2018) Sinem Karaman et al. DEVELOPMENT
- EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer
- (2018) Shaoxin Cai et al. EXPERIMENTAL CELL RESEARCH
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Tumor angiogenesis and anti‑angiogenic gene therapy for cancer (Review)
- (2018) Tinglu Li et al. Oncology Letters
- Tumor Angiogenesis: A Key Target for Cancer Therapy
- (2018) Dieter Marmé Oncology Research and Treatment
- A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.
- (2018) Nicolas Isambert et al. JOURNAL OF CLINICAL ONCOLOGY
- PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma
- (2018) Tianrun Liu et al. Nature Communications
- COPD-Type lung inflammation promotes K-ras mutant lung cancer through epithelial HIF-1α mediated tumor angiogenesis and proliferation
- (2018) Maria Miguelina De la Garza et al. Oncotarget
- Tumor microenvironment: Interactions and therapy
- (2018) Masoud Najafi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Prognostic role of HPV infection in esophageal squamous cell carcinoma
- (2018) Laura Bognár et al. Infectious Agents and Cancer
- Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
- (2017) Keehoon Jung et al. JOURNAL OF CLINICAL INVESTIGATION
- Therapeutic targeting of the angiopoietin–TIE pathway
- (2017) Pipsa Saharinen et al. NATURE REVIEWS DRUG DISCOVERY
- Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- (2017) Ghassan K. Abou‐Alfa et al. ONCOLOGIST
- Targeting CXCR4-dependent immunosuppressive Ly6Clowmonocytes improves antiangiogenic therapy in colorectal cancer
- (2017) Keehoon Jung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy
- (2017) Biagio Ricciuti et al. SEMINARS IN CANCER BIOLOGY
- Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
- (2017) M. Wroblewski et al. Nature Communications
- Erratum: Acute myeloid leukemia targets for bispecific antibodies
- (2017) S S Hoseini et al. Blood Cancer Journal
- Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors
- (2017) Nadine Mahfouz et al. PLoS One
- Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects
- (2016) Dong Li et al. CANCER LETTERS
- Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
- (2016) Florence T.H. Wu et al. CANCER RESEARCH
- Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- (2016) Jörg T Regula et al. EMBO Molecular Medicine
- The use of CrossMAb technology for the generation of bi- and multispecific antibodies
- (2016) Christian Klein et al. mAbs
- Angiocrine functions of organ-specific endothelial cells
- (2016) Shahin Rafii et al. NATURE
- Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
- (2016) Caroline Wigerup et al. PHARMACOLOGY & THERAPEUTICS
- Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
- (2016) Teresa E. Peterson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
- (2016) Jonas Kloepper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
- (2016) N. N. Rahbari et al. Science Translational Medicine
- The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance
- (2016) Lejla Alidzanovic et al. Oncotarget
- Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib-effective patients with advanced NSCLC
- (2016) Yijia Qin et al. Thoracic Cancer
- Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis
- (2015) Srimathi Srinivasan et al. ANGIOGENESIS
- Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
- (2015) Véronique Diéras et al. BREAST
- Anti-cancer activity of withaferin A in B-cell lymphoma
- (2015) MK McKenna et al. CANCER BIOLOGY & THERAPY
- PI3K–mTORC2 but not PI3K–mTORC1 Regulates Transcription of HIF2A/EPAS1 and Vascularization in Neuroblastoma
- (2015) Sofie Mohlin et al. CANCER RESEARCH
- A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2015) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Emerging roles of hypoxia-inducible factors and reactive oxygen species in cancer and pluripotent stem cells
- (2015) Shigeo Saito et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases
- (2015) Anna S. Berghoff et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma
- (2015) Enrica Borsi et al. Translational Research
- Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies
- (2015) Agnieszka Zimna et al. Biomed Research International
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
- (2014) M. Chiron et al. MOLECULAR CANCER THERAPEUTICS
- Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases
- (2014) A. S. Berghoff et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
- (2013) M Peeters et al. BRITISH JOURNAL OF CANCER
- Aflibercept
- (2013) K. K. Ciombor et al. CLINICAL CANCER RESEARCH
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- (2013) Y. Kienast et al. CLINICAL CANCER RESEARCH
- Angiopoietin signaling in the vasculature
- (2013) Lauri Eklund et al. EXPERIMENTAL CELL RESEARCH
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- VEGFA and tumour angiogenesis
- (2013) L. Claesson-Welsh et al. JOURNAL OF INTERNAL MEDICINE
- Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme
- (2013) Yasushi Soda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Double-antiangiogenic protein DAAP targeting vascular endothelial growth factor A and angiopoietins attenuates collagen-induced arthritis
- (2013) Young-Sool Hah et al. ARTHRITIS RESEARCH & THERAPY
- The Complex Role of Angiopoietin-2 in the Angiopoietin-Tie Signaling Pathway
- (2013) G. Thurston et al. Cold Spring Harbor Perspectives in Medicine
- Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
- (2012) M. M. Eatock et al. ANNALS OF ONCOLOGY
- Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors
- (2012) Yang-Fei Xiang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
- (2012) Brian Rini et al. CANCER
- Abstract 3290: REGN910, a fully-human, Ang2-specific monoclonal antibody, inhibits tumor growth as a monotherapy and dramatically potentiates the effects of VEGF Trap (aflibercept)
- (2012) Christopher Daly et al. CANCER RESEARCH
- Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets
- (2012) Janice A. Nagy et al. CLINICAL & EXPERIMENTAL METASTASIS
- A Heat-Shock Protein Axis Regulates VEGFR2 Proteolysis, Blood Vessel Development and Repair
- (2012) Alexander F. Bruns et al. PLoS One
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis
- (2011) M N Khan et al. BRITISH JOURNAL OF CANCER
- Hypoxia, stem cells and bone tumor
- (2011) Wen Zeng et al. CANCER LETTERS
- The Hypoxia-Associated Factor Switches Cells from HIF-1 - to HIF-2 -Dependent Signaling Promoting Stem Cell Characteristics, Aggressive Tumor Growth and Invasion
- (2011) M. Y. Koh et al. CANCER RESEARCH
- 1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway
- (2011) X. Pang et al. CARCINOGENESIS
- VEGF increases the proliferative capacity and eNOS/NO levels of endothelial progenitor cells through the calcineurin/NFAT signalling pathway
- (2011) Long Yang et al. CELL BIOLOGY INTERNATIONAL
- Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth
- (2011) H. Huang et al. CLINICAL CANCER RESEARCH
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
- (2011) W. Schaefer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
- (2011) Pipsa Saharinen et al. TRENDS IN MOLECULAR MEDICINE
- Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage
- (2010) Young Jun Koh et al. CANCER CELL
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
- (2010) H. Hashizume et al. CANCER RESEARCH
- Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas
- (2010) S.-S. Chae et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
- (2010) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
- (2010) K. Staufer et al. CURRENT CANCER DRUG TARGETS
- Abnormal embryonic lymphatic vessel development in Tie1 hypomorphic mice
- (2010) X. Qu et al. DEVELOPMENT
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR
- (2010) Jennifer S. Michaelson et al. mAbs
- A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
- (2010) J. L. Brown et al. MOLECULAR CANCER THERAPEUTICS
- Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody
- (2010) A. Coxon et al. MOLECULAR CANCER THERAPEUTICS
- Chemical generation of bispecific antibodies
- (2010) V. R. Doppalapudi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls
- (2010) J. E. Bohonowych et al. Journal of Oncology
- Loss of Endothelial Tie1 Receptor Impairs Lymphatic Vessel Development-Brief Report
- (2009) Gabriela D'Amico et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Endothelial deletion of hypoxia-inducible factor-2 (HIF-2 ) alters vascular function and tumor angiogenesis
- (2009) N. Skuli et al. BLOOD
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth
- (2009) Patrick Nasarre et al. CANCER RESEARCH
- Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
- (2009) N. Gaspar et al. CANCER RESEARCH
- Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives
- (2009) Zaher K. Otrock et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pathways mediating VEGF-independent tumor angiogenesis
- (2009) Napoleone Ferrara CYTOKINE & GROWTH FACTOR REVIEWS
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents
- (2009) Kenneth H. Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Angiopoietin-2 Exocytosis Is Stimulated by Sphingosine-1-Phosphate in Human Blood and Lymphatic Endothelial Cells
- (2008) Cholsoon Jang et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
- (2008) Y. Okawa et al. BLOOD
- VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis
- (2008) G Thurston et al. BRITISH JOURNAL OF CANCER
- Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells
- (2008) M. Calvani et al. CANCER RESEARCH
- The role of hypoxia-inducible factors in tumorigenesis
- (2008) E B Rankin et al. CELL DEATH AND DIFFERENTIATION
- SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers
- (2008) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
- (2008) E. I. Heath et al. CLINICAL CANCER RESEARCH
- Targeting Hsp90: small-molecule inhibitors and their clinical development
- (2008) Tony Taldone et al. CURRENT OPINION IN PHARMACOLOGY
- Dominant-Negative Hsp90 Reduces VEGF-Stimulated Nitric Oxide Release and Migration in Endothelial Cells
- (2007) Robert Q. Miao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PI3K/PTEN signaling in tumorigenesis and angiogenesis
- (2007) Bing-Hua Jiang et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Development and application of Hsp90 inhibitors
- (2007) D SOLIT DRUG DISCOVERY TODAY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started